Calculate exact reconstitution volumes, insulin units, and doses per vial for any peptide.
Thymosin Alpha-1 (often abbreviated Tα1) is a synthetic peptide composed of 28 amino acids and carrying an acetylated N-terminus. It corresponds to a naturally occurring fragment of the precursor protein prothymosin alpha, which is produced in the thymus gland. The thymus is the central organ for the maturation of T-lymphocytes, and the thymic factors it releases govern essential steps of adaptive immunity. Thymosin Alpha-1 was first isolated in the 1970s from the thymic extract Thymosin Fraction 5 and has since become one of the most intensively studied immune-modulating peptides.
Unlike repair peptides such as BPC-157 or TB-500, whose research focus lies in tissue healing and angiogenesis, Thymosin Alpha-1 is discussed primarily in the context of immune regulation. In preclinical and clinical models it has been studied in connection with strengthening the cell-mediated immune response, normalizing immune function under conditions of immunosuppression, and moderating excessive inflammatory reactions. Approved in several countries as a pharmaceutical under the brand name Zadaxin, Thymosin Alpha-1 is used there as an adjunct in chronic hepatitis B and C and as an immune-supporting agent. In the European Union and most Western markets it holds no marketing authorization as a medicine and therefore remains strictly within the research domain.
An important point of orientation: Thymosin Alpha-1 and Thymosin Beta-4 (TB-500) share only the historical name component "thymosin," because both were originally isolated from the same thymic fraction. Structurally and functionally they are entirely different. Thymosin Beta-4 is an actin-binding repair peptide, while Thymosin Alpha-1 is an immune modulator with no meaningful direct repair function. This distinction is critical for any research planning.
Thymosin Alpha-1 does not act through a single receptor but produces a broad spectrum of immunoregulatory effects. It behaves more like a biological switch that strengthens or rebalances the immune response depending on the starting state. The principal mechanisms characterized in research include:
Thymosin Alpha-1 is dosed in milligrams in research and is typically administered subcutaneously. Dosing is guided by the specific research question; most protocols use a fixed dose without an ascending titration.
Thymosin Alpha-1 is commonly supplied in 1.6 mg or 5 mg vials. Reconstituting a 5 mg vial with 1 mL of bacteriostatic water yields a concentration of 5 mg/mL (5,000 mcg/mL).
At a standard dose of 1.6 mg, a 5 mg vial provides three full doses plus a remainder. A 1.6 mg vial is often reconstituted with 1 mL of BAC water to a convenient concentration of 1.6 mg/mL, so that a full dose equals exactly 1 mL. Because vial sizes and reconstitution volumes vary widely, the precise injection volume should be determined individually for each protocol. The Thymosin Alpha-1 calculator above computes the exact volume for any combination of vial size, BAC water amount, and target dose.
Thymosin Alpha-1 is supplied as a lyophilized, freeze-dried powder in sealed vials and must be dissolved before use. For multi-dose vials, bacteriostatic water (BAC water) is the appropriate diluent, because its 0.9 percent benzyl alcohol content inhibits microbial growth and extends the usable window of the reconstituted solution. Sterile water for injection is suitable only for vials that will be fully consumed in a single session.
If the solution appears cloudy, discolored, or contains visible particulate matter, discard the vial and do not use it.
Thymosin Alpha-1 shows a consistently favorable tolerability profile across numerous preclinical and clinical investigations. As a fragment of an endogenous thymic protein, it has not produced organ toxicity, mutagenic effects, or hormonal disruption even at higher doses. Because it is an immune-modulating peptide, however, some aspects warrant particular attention.
In the published literature, few serious adverse events have been reported in approved clinical applications. Because Thymosin Alpha-1 is not authorized as a medicine in the EU and is supplied strictly for research purposes, consultation with a qualified healthcare professional before any use is strongly recommended.
Thymosin Alpha-1 covers a mechanism the classic repair peptides do not address: immune regulation. In research contexts it is therefore occasionally considered alongside BPC-157. While BPC-157 drives angiogenesis, collagen synthesis, and gastrointestinal healing, Thymosin Alpha-1 addresses the immunological component of recovery and stress. The two peptides act on fundamentally different axes and have essentially no mechanistic overlap.
Because of the shared name component, Thymosin Alpha-1 and TB-500 (Thymosin Beta-4) are frequently mentioned side by side in the research literature. Functionally, however, they are clearly distinct: TB-500 is an actin-binding repair and migration peptide, while Thymosin Alpha-1 is a pure immune modulator. Anyone considering both within a protocol should treat them as two independent tools serving different questions, not as related substances with similar effects.
For research questions around inflammation modulation, Thymosin Alpha-1 is sometimes considered alongside KPV. KPV is a short anti-inflammatory tripeptide that dampens pro-inflammatory signaling pathways, while Thymosin Alpha-1 regulates immune balance at the level of T-cell maturation. Both address the immune system from complementary angles: KPV more by dampening, Thymosin Alpha-1 more by rebalancing.
Thymosin Alpha-1 is not currently listed in the BergdorfBio range. Available peptides can be found in the BergdorfBio product catalog. All products are offered strictly for research purposes.
No. Both peptides carry the name component "thymosin" because they were historically isolated from the same thymic fraction, but they are structurally and functionally entirely different. Thymosin Alpha-1 is an immune-modulating peptide of 28 amino acids; Thymosin Beta-4 is an actin-binding repair peptide of 43 amino acids. They are not interchangeable.
In research, Thymosin Alpha-1 is usually injected subcutaneously, that is into the tissue just below the skin, most often in the abdominal area. Subcutaneous injection allows steady absorption. There is no reliable oral form, since the peptide would be broken down in the gastrointestinal tract.
Frequency ranges from twice to seven times per week depending on the research protocol. More intensive protocols use daily or near-daily dosing over a limited period, while others rely on two to three injections per week across longer cycles. An ascending titration is generally not required.
No. Thymosin Alpha-1 does not bind to hormone receptors and does not interact with the hypothalamic-pituitary axis, thyroid function, or sex hormones. It acts purely as an immune modulator, so no post-cycle therapy is required.
Research protocols frequently run over four to eight weeks, and longer in some questions. Because Thymosin Alpha-1 modulates immune balance, continuous use over many months without a break is uncommon in research. Specific cycle lengths depend entirely on the study design in question.
In some countries Thymosin Alpha-1 is approved as a prescription medicine under the brand name Zadaxin, for example as an adjunct in certain viral infections. In the European Union it holds no marketing authorization as a medicine. The material described here is supplied strictly for research purposes and is not intended for human use.
Thymosin Alpha-1 is not a growth factor and not an anabolic hormone. It does not fall into the same category as performance-enhancing peptides. Athletes subject to anti-doping regulations should nonetheless always check the current WADA prohibited list, since classifications can change.
Although some users combine multiple peptides immediately before injection, it is safer to reconstitute each peptide individually and inject them separately. Combined stability in solution is often not characterized, and separate injections eliminate dosing errors and undesirable in-solution interactions.
Medical Disclaimer: The information on this page is provided for educational and research purposes only. Thymosin Alpha-1 is not an approved medicine in the European Union and is supplied strictly for research use. Nothing on this page constitutes medical advice, a diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before considering any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.